A Complete Guide to How Cannabinoids Work as Medicine
A pharmacology review cataloged cannabinoid therapeutic properties including analgesia, muscle relaxation, immunosuppression, anti-inflammation, mood improvement, appetite stimulation, neuroprotection, and antitumor effects across CB1, CB2, and other receptors.
Quick Facts
What This Study Found
THC acts as an agonist at both CB1 and CB2 receptors distributed across the central nervous system and peripheral tissues including spleen, leukocytes, reproductive and urinary tracts, endocrine glands, arteries, and heart. Five endogenous cannabinoids had been identified, with anandamide and 2-AG best characterized. Evidence suggested additional cannabinoid receptor subtypes and vanilloid receptors were involved in cannabinoid functions.
The review cataloged therapeutic properties: analgesia, muscle relaxation, immunosuppression, anti-inflammation, anti-allergic effects, sedation, mood improvement, appetite stimulation, anti-emesis, lowering of intraocular pressure, bronchodilation, neuroprotection, and antineoplastic effects. Strategies to enhance endocannabinoid activity included inhibiting reuptake and degradation.
Key Numbers
Two receptor subtypes (CB1, CB2) cloned. Five endocannabinoids identified. Thirteen therapeutic properties cataloged.
How They Did This
This was a pharmacological review covering cannabinoid receptor distribution, endocannabinoid biology, therapeutic properties, and pharmacological strategies for modulating the endocannabinoid system.
Why This Research Matters
This review provided a comprehensive pharmacological reference for the expanding field of cannabinoid therapeutics. By mapping receptor distribution across the body and linking it to specific therapeutic properties, it helped explain the broad therapeutic potential of cannabinoids and guide drug development.
The Bigger Picture
The pharmacological framework described here has been significantly expanded. Additional endocannabinoids and receptor targets have been identified, and several cannabinoid-based medications have entered clinical use. The concept of modulating endocannabinoid tone rather than directly activating receptors has become a major research direction.
What This Study Doesn't Tell Us
The broad scope limited depth on individual therapeutic applications. The review was primarily descriptive rather than critically evaluating evidence quality for each application.
Questions This Raises
- ?How many additional cannabinoid receptor subtypes have been identified since this review?
- ?Which of the thirteen therapeutic properties have the strongest clinical evidence?
Trust & Context
- Key Stat:
- 13 therapeutic properties across CB1 and CB2 receptors in brain, immune, and organ systems
- Evidence Grade:
- This is a comprehensive pharmacological review providing moderate-level evidence through systematic cataloging of mechanisms and applications.
- Study Age:
- Published in 2004. The endocannabinoid system has been extensively characterized since this review.
- Original Title:
- Pharmacology of cannabinoids.
- Published In:
- Neuro endocrinology letters, 25(1-2), 14-23 (2004)
- Authors:
- Grotenhermen, Franjo(4)
- Database ID:
- RTHC-00165
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Where are cannabinoid receptors located in the body?
CB1 receptors are primarily in the central and peripheral nervous system, while CB2 receptors are mainly in immune cells. Both types are also found in the spleen, reproductive and urinary tracts, endocrine glands, blood vessels, and heart.
How many different medical effects do cannabinoids have?
This review cataloged 13 distinct therapeutic properties: pain relief, muscle relaxation, immune suppression, anti-inflammation, anti-allergy, sedation, mood improvement, appetite stimulation, anti-nausea, eye pressure reduction, bronchodilation, neuroprotection, and antitumor effects.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
- full-spectrum-vs-broad-spectrum-vs-isolate
Cite This Study
https://rethinkthc.com/research/RTHC-00165APA
Grotenhermen, Franjo. (2004). Pharmacology of cannabinoids.. Neuro endocrinology letters, 25(1-2), 14-23.
MLA
Grotenhermen, Franjo. "Pharmacology of cannabinoids.." Neuro endocrinology letters, 2004.
RethinkTHC
RethinkTHC Research Database. "Pharmacology of cannabinoids." RTHC-00165. Retrieved from https://rethinkthc.com/research/grotenhermen-2004-pharmacology-of-cannabinoids
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.